Suzetrigine (Journavx / VX-548)
Sleep & Recovery · Selective Nav1.8 sodium channel inhibitor
Tier A+
What this is
Vertex Pharmaceuticals. First new acute pain mechanism in decades. Major clinical relevance because it offers non-opioid acute pain relief — directly addressing the opioid crisis. Vertex pricing ~$15-20/dose vs ~$1 for generic opioids is the practical adoption challenge. Currently studied in chronic pain (DPN, lumbosacral radiculopathy) but Phase 2 chronic results were less impressive — efficacy may be acute-pain-specific.
Mechanism
Selective inhibitor of voltage-gated sodium channel Nav1.8 expressed almost exclusively on peripheral pain-sensing neurons; blocks pain signal transmission peripherally without CNS effects — no opioid receptor activity, no abuse potential, no sedation; first-in-class non-opioid acute pain mechanism
Dose & route
100 mg PO loading dose then 50 mg PO every 12 hours
Citations
- https://doi.org/10.1056/NEJMoa2401077
- https://pubmed.ncbi.nlm.nih.gov/41842993/
- https://pubmed.ncbi.nlm.nih.gov/41867732/
- https://doi.org/10.12775/jehs.2026.90.70122
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.